Actualités

Bristol-Myers Squibb stock has delivered a 38.1% gain over the past year, while valuation work using a Discounted Cash Flow (DCF) intrinsic value estimate and earnings multiples both currently point to the shares trading at a discount to that estimate. For investors, that combination of strong recent returns and a still supportive valuation framework raises the question of how much margin of safety may remain in the current price. The 38.1% one year return shows that sentiment toward...

Sycamore Capital Management, a franchise of Victory Capital Management, released its Q2 2026 investor letter for “Sycamore Mid Cap Value Equity Strategy”. A copy of the letter can be downloaded here. Sycamore Capital’s Mid Cap Value investment team focuses on a bottom-up approach to identify undervalued businesses with growth potential. In Q2 2026, the strategy […]

Makan Delrahim made the disclosure at Politico’s California Agenda conference, according to Reuters, signaling that Paramount is willing to go beyond internal safeguards to salvage a deal that has become one of the most politically charged media mergers in years. Warner Bros. Discovery is the publicly traded parent of CNN (NASDAQ: WBD), and the merger’s fate directly determines whether Ellison’s Paramount consolidates control over both CBS News and the cable network.

mFLUSIVA is now the first and only mRNA standalone seasonal influenza vaccine on the market, marking a major advancement for the field.

Johnson & Johnson (NYSE:JNJ) has officially entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system. The authorization represents an important milestone for J&J’s MedTech ambitions, but the company is entering a market in which Intuitive Surgical (NASDAQ:ISRG) already has an extensive installed base, established surgeon […]

Firefox developer Mozilla is warning that it could be forced to "exit the browser and browser engine markets" if it can no longer receive payment from Google for distributing its search engine.

Dismissal removes one legal challenge involving compounded alternatives while Novo confronts intensifying commercial competition in obesity treatments.

A Texas judge dismissed claims that the drugmakers illegally blocked access to compounded weight-loss drugs.

Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!

Moderna (NASDAQ:MRNA) announced on Thursday that the U. S.

The Food and Drug Administration approved Moderna’s mRNA-based flu vaccine for adults ages 50 and older, clearing the first shot of its kind after a review process that nearly collapsed in February. The vaccine, called mFlusiva, uses the same mRNA technology as Moderna’s Covid-19 shots. It could reach pharmacies in time for the coming flu season, which typically starts in the fall.

(Update with New Jersey Attorney General Jennifer Davenport's statement on the lawsuit in the penult

Amazon.com (AMZN) stock is in focus after a consumer lawsuit filed on July 31, 2026, alleged the retailer sold Orgain protein powder containing harmful levels of heavy metals and misrepresented the products’ safety and quality attributes. See our latest analysis for Amazon.com. After the latest lawsuit headlines, Amazon.com’s recent share price moves still reflect strong momentum, with a 7 day share price return of 23.03% and a 1 year total shareholder return of 32.87%, which points to...

A European court rejected Broadcom's attempt to block regulators from demanding U.S.-based VMware legal documents.

California’s governor warns that an antitrust lawsuit threatening the media mega-merger could severely damage local entertainment industry jobs.

The California governor has told people involved in the suit that blocking the $81 billion deal could harm Hollywood jobs.

LONDON, July 27 (Reuters) - Elon Musk's Tesla on Monday won its bid to revive a London lawsuit brought against U.S. technology firm InterDigital and a patent licensing platform, seeking a patent

The new findings position Lilly to file an application for the highly anticipated medicine, but also leave some questions about the additive benefits a “triple-G” drug has on heart health.

Court strips shareholder case of class-action status

Investing.com -- Apple Inc. and the US Justice Department are in early discussions to settle a 2024 antitrust lawsuit, Bloomberg reported Friday.

Apple ‌and ‌the U.S. Department ​of Justice are in ‌early ⁠discussions about settling ⁠a 2024 ​lawsuit ​that ​alleges the ‌iPhone maker violated antitrust laws, ‌Bloomberg ​News ​reported ​on ‌Friday. Reuters could not ​immediately ​verify the ​report. (Reporting ‌by Jaspreet ​Singh in ​Bengaluru)

(Bloomberg) -- Apple Inc. and the US Justice Department are in early discussions about settling a 2024 lawsuit that alleges the iPhone maker violated antitrust laws. Most Read from BloombergFCC Near Rulings Against Disney Over ‘The View,’ TV LicensesChip Stocks Poised for Bear Market in AI Unwind: Markets WrapGoogle Gemini Launch Delayed as Tech Falls Short of Internal GoalsChina’s Moonshot Unveils AI Model That Narrows Gap With US FirmsThailand Scraps Plan to End Visa-Free Entry for Indian Tour

The daily medication is expected to be list-priced at $10.50 per pill. Here's what to know about Merck's new cholesterol drug Lipfendra.

Lipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins alone can achieve.

European cloud and infrastructure groups have challenged Broadcom over recent VMware licensing changes following the acquisition. Trade association CISPE and others have asked EU antitrust regulators to review and suspend certain Broadcom practices tied to VMware contracts. The European Commission has opened an antitrust review that centers on access, pricing, and conditions for VMware software in the region. Broadcom (NasdaqGS:AVGO) is coming under closer regulatory scrutiny in Europe at a...

Pfizer Inc. (NYSE:PFE) is one of the 8 Worst Blue Chip Stocks to Buy Now. On July 10, 2026, Pfizer Inc. (NYSE:PFE) and Astellas Pharma (ALPMY) announced that the U.S. Food and Drug Administration approved PADCEV, a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor Keytruda or Keytruda QLEX as neoadjuvant and adjuvant treatment for […]

Just one day after glowing reviews, a surprise revenue warning sent the stock into a tailspin and brought lawyers to the door.

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

Alphabet unit Google on Wednesday urged Europe's top court to dismiss EU antitrust regulators' appeal ‌against a lower court ruling that scrapped a €1.49 billion ($1.7 billion) fine, saying ‌the regulators' arguments were flawed. The dispute reached the Court of Justice of the European Union ​after regulators appealed a 2024 General Court ruling that annulled the fine imposed on Google in 2019. The lower court cited errors in the European Commission's assessment of the case.

Gedatolisib, in-licensed from Pfizer in 2021, is Celcuity’s sole late-stage asset.